USPTO serial 79219758
ALGRY SMART CHOLINE
Reviewed by CopyMark Law Group
Reg. 5592417Status 709
- Filing date
- Status date
- Registration date
- Oct 30, 2018
- Examiner
- BEVERLY, JOSETTE MICHELLE
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with ALGRY SMART CHOLINE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
JOSE MARIA ARRUFAT
JOSE MARIA ARRUFAT ARRUFAT GRACIA PLLC54 WEST, 40TH STREET, SUITE 816NEW YORK, NY 10018UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical products, namely, pharmaceutical preparations and pharmaceutical substances and nutraceuticals for its use as dietary supplements for prenatal support and for the normal development of the brain and the development of the memory center in the uterus; pharmaceutical products, namely, pharmaceutical preparations and pharmaceutical substances and nutraceuticals for its use as dietary supplements for the development of the brain in infants; pharmaceutical products, namely, pharmaceutical preparations and pharmaceutical substances and nutraceuticals for its use as dietary supplements for the development of memory in children; pharmaceutical products products, namely, pharmaceutical preparations and pharmaceutical substances and nutraceuticals for its use as dietary supplements for the prevention of defects in the neural tube during fetal development; pharmaceutical products, namely, pharmaceutical preparations and pharmaceutical substances and nutraceuticals for its use as dietary supplements for health and normal liver functions; pharmaceutical products, namely, pharmaceutical preparations and pharmaceutical substances and nutraceuticals for its use as dietary supplements for promoting healthy heart conditions; pharmaceutical products, namely, pharmaceutical preparations and pharmaceutical substances and nutraceuticals for its use as dietary supplements to promote cerebral/cognitive health; pharmaceutical products, namely, pharmaceutical preparations and pharmaceutical substances and nutraceuticals for its use as dietary supplements for the health of the liver; pharmaceutical products, namely, pharmaceutical preparations and pharmaceutical substances and nutraceuticals for its use as dietary supplements for sports nutrition; food for babies; disinfectants; sanitary preparations for medical use; dietetic foods and beverages adapted for medical use; food supplements for humans and animals; plasters for medical purposes; materials for dental fillings and dental impressions; preparations for destroying vermin; fungicides; herbicides; pharmaceutical preparations and substances for the prevention and treatment of normal brain development and development of the memory center of prenatal in uterus during pregnancy, for the prevention and treatment of disease and disorders of brain and memory development in children, for the prevention of neural tube defects in fetal development, for prevention and treatment of diseases and disorders of liver, for prevention and treatment of diseases and disorders of heart, for prevention and treatment of diseases and disorders of brain, for the prevention of diseases and disorders of neural defects during fetal development; veterinary preparations for the prevention of diseases and disorders of brain during fetal development in pregnancy phase of animals, for the prevention and treatment of diseases and disorders of brain in newborn animals, for the prevention and treatment of diseases and disorders of liver, heart and brain of animals, for the prevention of neural diseases and neural disorders during fetal development, for its use as food supplement for animals; pharmaceutical preparations for health care for the prevention of brain, liver and heart diseases; medicated serums for the treatment of brain, liver and heart diseases; vaccines | SECTION 71 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by ALGRY QUIMICA, S.L.
- Other trademarks owned by ALGRY QUIMICA, S.L.
- Other trademarks owned by ALGRY QUIMICA, S.L.
- Other trademarks owned by ALGRY QUIMICA, S.L.
- Other trademarks in Class 005
- Similar marks named ALGRY SMART CHOLINE
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 3, 2026 | INNT | TOTAL INVALIDATION PROCESSED BY THE IB | — |
| Aug 20, 2026 | INTS | TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB | — |
| Aug 20, 2026 | INPC | INVALIDATION PROCESSED | — |
| Jan 16, 2026 | INTR | TOTAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| May 16, 2025 | C71T | CANCELLED SECTION 71 | — |
| May 1, 2025 | ADCH | CHANGE OF NAME/ADDRESS REC'D FROM IB | — |
| Jan 9, 2025 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Oct 30, 2023 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Oct 21, 2019 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 21, 2019 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Oct 4, 2019 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 4, 2019 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Mar 1, 2019 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Feb 7, 2019 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Feb 7, 2019 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Jan 30, 2019 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Oct 30, 2018 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Aug 14, 2018 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Aug 14, 2018 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Aug 11, 2018 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Jul 25, 2018 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Jul 25, 2018 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jul 25, 2018 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Jul 3, 2018 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jun 7, 2018 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jun 6, 2018 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jun 6, 2018 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Dec 23, 2017 | RFNT | REFUSAL PROCESSED BY IB | — |
| Dec 6, 2017 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Dec 6, 2017 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Nov 22, 2017 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Nov 21, 2017 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 14, 2017 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Nov 9, 2017 | DOCK | ASSIGNED TO EXAMINER | — |
| Nov 9, 2017 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Nov 8, 2017 | LIMI | LIMITATION FROM ORIGINAL APPLICATION ENTERED | — |
| Nov 2, 2017 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |